Aqualung Takes Genomic Approach to COVID-19’s Killer Lung Inflammation
Targets Protein Linked To Acute Respiratory Distress Syndrome
Executive Summary
Acute respiratory distress syndrome is one of the prime causes behind the mounting global death toll of COVID-19, but there are currently no FDA-approved treatments. Armed with biomarker and genotyping assays, Aqualung hopes to speed its antibody candidate into development by next year.